Tag: ramucirumab

May 13, 2019 Off

Lilly gets fifth FDA approval for Cyramza

Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).

March 12, 2019 Off

Cyramza plus erlotinib delays disease progression in lung cancer patients

By Dino Mustafić

Eli Lilly’s Phase 3 RELAY study of Cyramza showed improvement in the time patients lived without their cancer growing or spreading after starting treatment, the company said Tuesday.